Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 612,418
  • Shares Outstanding, K 68,811
  • Annual Sales, $ 43,270 K
  • Annual Income, $ -130,870 K
  • EBIT $ -161 M
  • EBITDA $ -166 M
  • 60-Month Beta 1.61
  • Price/Sales 14.36
  • Price/Cash Flow N/A
  • Price/Book 2.08

Options Overview Details

View History
  • Implied Volatility 80.55% ( +5.23%)
  • Historical Volatility 80.57%
  • IV Percentile 31%
  • IV Rank 35.48%
  • IV High 195.01% on 04/08/25
  • IV Low 17.61% on 07/18/24
  • Put/Call Vol Ratio 1.11
  • Today's Volume 297
  • Volume Avg (30-Day) 236
  • Put/Call OI Ratio 2.18
  • Today's Open Interest 18,087
  • Open Int (30-Day) 17,646

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.67
  • Number of Estimates 4
  • High Estimate -0.49
  • Low Estimate -0.83
  • Prior Year -0.58
  • Growth Rate Est. (year over year) -15.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.45 +61.50%
on 05/23/25
9.60 -8.23%
on 06/17/25
+2.68 (+43.72%)
since 05/16/25
3-Month
3.91 +125.32%
on 04/09/25
9.60 -8.23%
on 06/17/25
+2.18 (+32.88%)
since 03/17/25
52-Week
3.91 +125.32%
on 04/09/25
13.98 -37.00%
on 10/28/24
-0.20 (-2.22%)
since 06/17/24

Most Recent Stories

More News
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 8.81 (-1.01%)
Breakout Momentum Plays You May Not Know About

Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.

NVMI : 228.04 (-1.04%)
OUST : 18.99 (-4.62%)
EYPT : 8.81 (-1.01%)
EyePoint Announces Participation at Upcoming Investor Conferences

EYPT : 8.81 (-1.01%)
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYUâ„¢ for Treatment of Wet Age-Related Macular Degeneration

EYPT : 8.81 (-1.01%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 8.81 (-1.01%)
EyePoint Announces Participation at Upcoming Investor Conferences

EYPT : 8.81 (-1.01%)
EyePoint Pharmaceuticals: Q1 Earnings Snapshot

EyePoint Pharmaceuticals: Q1 Earnings Snapshot

EYPT : 8.81 (-1.01%)
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EYPT : 8.81 (-1.01%)
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

EYPT : 8.81 (-1.01%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 8.81 (-1.01%)

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 10.17
2nd Resistance Point 9.88
1st Resistance Point 9.35
Last Price 8.81
1st Support Level 8.53
2nd Support Level 8.24
3rd Support Level 7.71

See More

52-Week High 13.98
Fibonacci 61.8% 10.14
Fibonacci 50% 8.95
Last Price 8.81
Fibonacci 38.2% 7.76
52-Week Low 3.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar